[1]

Hiromatsu Y, Wall JR, Kahaly GJ, et al. Graves ' Orbitopathy[J/OL]. Int J Endocrinol, 2015, 2015: 634234 [2018-07-29]. https://www.hindawi.com/journals/ije/2015/634234. DOI: 10.1155/2015/634234.
[2] Gould DJ, Roth FS, Soparkar CNS.  The diagnosis and treatment of thyroid-associated ophthalmopathy[J]. Aesthetic Plast Surg, 2012, 36(3): 638-648.   doi: 10.1007/s00266-011-9843-4
[3] Bartalena L, Baldeschi L, Boboridis K, et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.   doi: 10.1159/000443828
[4] Jiang H, Wang ZC, Xian JF, et al.  Evaluation of rectus extraocular muscles using dynamic contrast-enhanced MR imaging in patients with Graves′ ophthalmopathy for assessment of disease activity[J]. Acta Radiol, 2012, 53(1): 87-94.   doi: 10.1258/ar.2011.110431
[5] 罗莎, 王雪, 刘黎洁, 等.  99Tcm-奥曲肽SPECT/CT对活动期甲状腺相关性眼病治疗的效果评价[J]. 眼科, 2013, 22(5): 309-312.
Luo S, Wang X, Liu LJ, et al.  The evaluation of treatment effect of active thyroid associated ophthalmopathy with 99Tcm labeled octreotide SPECT/CT[J]. Ophthalmol China, 2013, 22(5): 309-312.
[6] Szabados L, Nagy EV, Ujhelyi B, et al.  The impact of 99Tcm-DTPA orbital SPECT in patient selection for external radiation therapy in Graves' ophthalmopathy[J]. Nucl Med Commun, 2013, 34(2): 108-112.   doi: 10.1097/MNM.0b013e32835c19f0
[7] Ujhelyi B, Erdei A, Galuska L, et al.  Retrobulbar 99Tcm-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy[J]. Thyroid, 2009, 19(4): 375-380.   doi: 10.1089/thy.2008.0298
[8] Galuska L, Leovey A, Szucs-Farkas Z, et al.  Imaging of disease activity in Graves' orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores[J]. Nucl Med Commun, 2005, 26(5): 407-414.   doi: 10.1097/00006231-200505000-00003
[9] 李方都, 褚俏梅, 张立颖, 等.  99Tcm-DTPA眼眶显像用于甲状腺相关眼病患者综合评价[J]. 中国实用眼科杂志, 2015, 33(9): 1008-1012.   doi: 10.3760/cma.j.issn.1006-4443.2015.09.014
Li FD, Chu QM, Zhang LY, et al.  The value of 99Tcm-DTPA orbital SPECT used in the comprehensive evaluation of patient with thyroid associated ophthalmopathy[J]. Chin J Pract Ophthalmol, 2015, 33(9): 1008-1012.   doi: 10.3760/cma.j.issn.1006-4443.2015.09.014
[10] 杨宝军, 李险峰, 陆克义, 等.  99Tcm-DTPA眼眶显像在甲状腺相关性眼病中的临床应用[J]. 山西医科大学学报, 2009, 40(6): 563-566.   doi: 10.3969/j.issn.1007-6611.2009.06.027
Yang BJ, Li XF, Lu KY, et al.  Clinical value of 99Tcm-DTPA orbital scan in thyroid associated opthalmopathy[J]. J Shanxi Med Univ, 2009, 40(6): 563-566.   doi: 10.3969/j.issn.1007-6611.2009.06.027
[11] 杨宝军, 李险峰, 陆克义, 等.  99Tcm-二亚乙基三胺五乙酸与99Tcm-奥曲肽眼眶显像在甲状腺相关性眼病中的对比研究[J]. 国际放射医学核医学杂志, 2009, 33(1): 22-25.   doi: 10.3760/cma.j.issn.1673-4114.2009.01.022
Yang BJ, Li XF, Lu KY, et al.  A comparative study of 99Tcm-diethylene triaminepentaacetic acid and 99Tcm-octreotide orbital scan in thyroid associated ophthalmopathy[J]. Int J Radiat Med Nucl Med, 2009, 33(1): 22-25.   doi: 10.3760/cma.j.issn.1673-4114.2009.01.022
[12] Alevizaki-Harhalaki M, Alevizaki C, Georgiou E, et al.  Increased Tc-99m DTPA uptake in active Graves' ophthalmopathy and pretibial myxoedema[J]. J Nucl Med, 1983, 24(2): 174-176.
[13] Galuska L, Leovey A, Szucs-Farkas Z, et al.  SPECT using 99Tcm-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI[J]. Nucl Med Commun, 2002, 23(12): 1211-1216.   doi: 10.1097/01.mnm.0000046214.83338.50
[14] 张雪辉, 孔飚, 肖国有, 等.  SPECT/CT显像对脊柱良恶性病变诊断的增益价值[J]. 中华核医学与分子影像学杂志, 2016, 36(2): 156-160.   doi: 10.3760/cma.j.issn.2095-2848.2016.02.013
Zhang XH, Kong B, Xiao GY, et al.  The added value of SPECT/CT imaging for diagnosing benign and malignant lesions of spine[J]. Chin J Nucl Med Mol Imaging, 2016, 36(2): 156-160.   doi: 10.3760/cma.j.issn.2095-2848.2016.02.013